Last reviewed · How we verify
Concurrent PD-1 antibody
Concurrent PD-1 antibody is a PD-1 inhibitor Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Cancer (specific indication not yet defined in phase 3). Also known as: Concurrent immunotherapy.
A PD-1 antibody that blocks the PD-1 checkpoint protein on T cells, allowing the immune system to recognize and attack cancer cells.
Concurrent PD-1 antibody is not mentioned in the provided facts. However, based on the information given, a related treatment is being studied in combination with Bevacizumab and Lomustine for various conditions, including Glioblastoma, Locally Advanced Rectal Cancer, and Hypopharyngeal Carcinoma.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Concurrent PD-1 antibody |
|---|---|
| Also known as | Concurrent immunotherapy |
| Sponsor | Sun Yat-sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PD-1 inhibitors work by releasing the 'brakes' on T cell-mediated immunity. Cancer cells often express PD-L1, which binds to PD-1 on T cells and suppresses anti-tumor immune responses. By blocking this interaction, PD-1 antibodies restore T cell activation and proliferation, enabling durable anti-tumor immunity. The term 'concurrent' suggests this agent may be used in combination with other therapies.
Approved indications
- Cancer (specific indication not yet defined in phase 3)
Common side effects
- Fatigue
- Immune-related adverse events (irAEs)
- Pneumonitis
- Hepatotoxicity
- Colitis
Key clinical trials
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (PHASE2)
- PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (PHASE2)
- Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer (PHASE2)
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (PHASE3)
- A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (PHASE3)
- Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC (PHASE2)
- Window of Opportunity in Preserving Laryngeal Function Trial (PHASE2)
- A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Concurrent PD-1 antibody CI brief — competitive landscape report
- Concurrent PD-1 antibody updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Concurrent PD-1 antibody
What is Concurrent PD-1 antibody?
How does Concurrent PD-1 antibody work?
What is Concurrent PD-1 antibody used for?
Who makes Concurrent PD-1 antibody?
Is Concurrent PD-1 antibody also known as anything else?
What drug class is Concurrent PD-1 antibody in?
What development phase is Concurrent PD-1 antibody in?
What are the side effects of Concurrent PD-1 antibody?
What does Concurrent PD-1 antibody target?
Related
- Drug class: All PD-1 inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Cancer (specific indication not yet defined in phase 3)
- Also known as: Concurrent immunotherapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing